-
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures
Guideline addresses the management of psoriasis with topical therapies, alterative and complementary medicine and the tools to assess psoriasis severity
-
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
Guideline addresses the use of TNF‑α inhibitors, IL‑12/23 inhibitors, IL‑17 inhibitors, and IL‑23 inhibitors (monoclonal antibodies) that target specific immune pathways involved in inflammation
-
Joint AAD-NPF guidelines of care for the management of psoriasis with systemic nonbiologic therapies
Guideline provides evidence‑based recommendations for using oral systemic treatments like immunosuppressants, retinoids, and phosphodiesterase‑4 inhibitors to manage moderate to severe psoriasis
-
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with phototherapy
Guideline addresses multiple phototherapy treatment options ranging from widely used ultraviolet modalities to the combined use of photosensitizing agents to newer and less prevalent choices
-
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities
Guideline addresses the management of extracutaneous manifestations of psoriasis in adults, including comorbid conditions, mental health, psychosocial wellness, and quality of life (QoL)
